Global and Japan Infliximab and biosimilar Market 2020 by Manufacturers, Type and Application, Forecast to 2025
Market Overview
The global Infliximab and biosimilar market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Infliximab and biosimilar market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Infliximab and biosimilar market is split by Type and Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Breakdown by Type, Infliximab and biosimilar market has been segmented into Infliximab, infliximab-dyyb, infliximab-abda, etc.
Breakdown by Application, Infliximab and biosimilar has been segmented into Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, etc.
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Infliximab and biosimilar market presented in the report. This section sheds light on the sales growth of different regional and country-level Infliximab and biosimilar markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Infliximab and biosimilar market.
For Japan, this report analyses the Japan market by players, Type and Application, for the period 2015-2025.
Competitive Landscape and Infliximab and biosimilar Market Share Analysis
Infliximab and biosimilar competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, Infliximab and biosimilar sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Infliximab and biosimilar sales, revenue and market share for each player covered in this report.
The major players covered in Infliximab and biosimilar are: Janssen Biotech, Merck and Co., Pfizer, etc. Among other players domestic and global, Infliximab and biosimilar market share data is available for global, North America, Europe, Asia, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The key market players for global Infliximab and biosimilar market are listed below:
Janssen Biotech
Merck and Co.
Pfizer
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)
Market segment by Type, covers:
Infliximab
infliximab-dyyb
infliximab-abda
Market segment by Application, can be divided into
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Table of Contents
1 Market Overview
1.1 Infliximab and biosimilar Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Infliximab and biosimilar Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Infliximab
1.2.3 infliximab-dyyb
1.2.4 infliximab-abda
1.3 Market Analysis by Application
1.3.1 Overview: Global Infliximab and biosimilar Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Crohn's Disease
1.3.3 Pediatric Crohn's Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Global Infliximab and biosimilar Market Size and Forecast (2015-2025)
1.4.1 Global Infliximab and biosimilar Revenue and Forecast (2015-2025)
1.4.2 Global Infliximab and biosimilar Sales and Forecast (2015-2025)
1.5 Global Infliximab and biosimilar Market Size Overview by Geography (2015-2020)
2 Manufacturers Profiles
2.1 Janssen Biotech
2.1.1 Janssen Biotech Details
2.1.2 Janssen Biotech Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Janssen Biotech SWOT Analysis
2.1.4 Janssen Biotech Product and Services
2.1.5 Janssen Biotech Infliximab and biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck and Co.
2.2.1 Merck and Co. Details
2.2.2 Merck and Co. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck and Co. SWOT Analysis
2.2.4 Merck and Co. Product and Services
2.2.5 Merck and Co. Infliximab and biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer Infliximab and biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Global Infliximab and biosimilar Market, Company Landscape
3.1 Company Market Share Analysis: Global
3.1.1 Global Infliximab and biosimilar Sales and Market Share by Manufacturer (2018-2019)
3.1.2 Global Infliximab and biosimilar Revenue and Market Share by Manufacturer (2018-2019)
3.2 Company Market Share Analysis: Japan
3.2.1 Key Players Infliximab and biosimilar Sales in Japan (2018-2019)
3.2.2 Japan Infliximab and biosimilar Revenue Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Infliximab and biosimilar Manufacturer Market Share in 2019
3.3.2 Top 6 Infliximab and biosimilar Manufacturer Market Share in 2019
4 Market Size by Geography
4.1 Global Infliximab and biosimilar Market Size by Geography (2015-2020)
4.1.1 Global Infliximab and biosimilar Sales by Geography (2015-2020)
4.1.2 Global Infliximab and biosimilar Revenue by Regions (2015-2020)
4.2 Global Infliximab and biosimilar Market Size and Forecast by Regions (2020-2025)
4.2.1 Global Infliximab and biosimilar Sales and Forecast by Regions (2020-2025)
4.2.2 Global Infliximab and biosimilar Revenue and Forecast by Regions (2020-2025)
4.3 North America Infliximab and biosimilar Market Size and Forecast (2015-2025)
4.4 Europe Infliximab and biosimilar Market Size and Forecast (2015-2025)
4.5 Asia-Pacific Infliximab and biosimilar Market Size and Forecast (2015-2025)
4.6 South America Infliximab and biosimilar Market Size and Forecast (2015-2025)
4.7 Middle East and Africa Infliximab and biosimilar Market Size and Forecast (2015-2025)
5 North America by Country
5.1 North America Infliximab and biosimilar Market Size by Country (2015-2020)
5.1.1 North America Infliximab and biosimilar Sales and Market Share by Country (2015-2020)
5.1.2 North America Infliximab and biosimilar Revenue and Market Share by Country (2015-2020)
5.2 North America Infliximab and biosimilar Market Size and Forecast by Country (2020-2025)
5.2.1 North America Infliximab and biosimilar Sales and Forecast by Country (2020-2025)
5.2.2 North America Infliximab and biosimilar Revenue and Forecast by Country (2020-2025)
5.3 United States Infliximab and biosimilar Market Size and Forecast (2015-2025)
5.4 Canada Infliximab and biosimilar Market Size and Forecast (2015-2025)
5.5 Mexico Infliximab and biosimilar Market Size and Forecast (2015-2025)
6 Europe by Country
6.1 Europe Infliximab and biosimilar Market Size by Country (2015-2020)
6.1.1 Europe Infliximab and biosimilar Sales by Country (2015-2020)
6.1.2 Europe Infliximab and biosimilar Revenue by Country (2015-2020)
6.2 Europe Infliximab and biosimilar Market Size and Forecast by Country (2020-2025)
6.2.1 Europe Infliximab and biosimilar Sales and Forecast by Country (2020-2025)
6.2.2 Europe Infliximab and biosimilar Revenue and Forecast by Country (2020-2025)
6.3 Germany Infliximab and biosimilar Market Size and Forecast (2015-2025)
6.4 United Kingdom Infliximab and biosimilar Market Size and Forecast (2015-2025)
6.5 France Infliximab and biosimilar Market Size and Forecast (2015-2025)
6.6 Russia Infliximab and biosimilar Market Size and Forecast (2015-2025)
6.7 Italy Infliximab and biosimilar Market Size and Forecast (2015-2025)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Infliximab and biosimilar Market Size by Region (2015-2020)
7.1.1 Asia-Pacific Infliximab and biosimilar Sales by Region (2015-2020)
7.1.2 Asia-Pacific Infliximab and biosimilar Revenue by Region (2015-2020)
7.2 Asia-Pacific Infliximab and biosimilar Market Size and Forecast by Region (2020-2025)
7.2.1 Asia-Pacific Infliximab and biosimilar Sales and Forecast by Region (2020-2025)
7.2.2 Asia-Pacific Infliximab and biosimilar Revenue and Forecast by Region (2020-2025)
7.3 China Infliximab and biosimilar Market Size and Forecast (2015-2025)
7.4 Japan Infliximab and biosimilar Market Size and Forecast (2015-2025)
7.5 Korea Infliximab and biosimilar Market Size and Forecast (2015-2025)
7.6 India Infliximab and biosimilar Market Size and Forecast (2015-2025)
7.7 Southeast Asia Infliximab and biosimilar Market Size and Forecast (2015-2025)
7.8 Australia Infliximab and biosimilar Market Size and Forecast (2015-2025)
8 South America by Country
8.1 South America Infliximab and biosimilar Market Size by Country (2015-2020)
8.1.1 South America Infliximab and biosimilar Sales by Country (2015-2020)
8.1.2 South America Infliximab and biosimilar Revenue by Country (2015-2020)
8.2 South America Infliximab and biosimilar Market Size and Forecast by Country (2020-2025)
8.2.1 South America Infliximab and biosimilar Sales and Forecast by Country (2020-2025)
8.2.2 South America Infliximab and biosimilar Revenue and Forecast by Country (2020-2025)
8.3 Brazil Infliximab and biosimilar Market Size and Forecast (2015-2025)
8.4 Argentina Infliximab and biosimilar Market Size and Forecast (2015-2025)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Infliximab and biosimilar Market Size by Country (2015-2020)
9.1.1 Middle East & Africa Infliximab and biosimilar Sales by Country (2015-2020)
9.1.2 Middle East & Africa Infliximab and biosimilar Revenue by Country (2015-2020)
9.2 Middle East & Africa Infliximab and biosimilar Market Size and Forecast by Country (2020-2025)
9.2.1 Middle East & Africa Infliximab and biosimilar Sales and Forecast by Country (2020-2025)
9.2.2 Middle East & Africa Infliximab and biosimilar Revenue and Forecast by Country (2020-2025)
9.3 Saudi Arabia Infliximab and biosimilar Market Size and Forecast (2015-2025)
9.4 Turkey Infliximab and biosimilar Market Size and Forecast (2015-2025)
9.5 Egypt Infliximab and biosimilar Market Size and Forecast (2015-2025)
9.6 South Africa Infliximab and biosimilar Market Size and Forecast (2015-2025)
10 Market Segment by Type
10.1 Global Infliximab and biosimilar Market Size by Type (2015-2020)
10.1.1 Global Infliximab and biosimilar Sales by Type (2015-2020)
10.1.2 Global Infliximab and biosimilar Revenue by Type (2015-2020)
10.1.3 Global Infliximab and biosimilar Price by Type (2015-2020)
10.2 Global Infliximab and biosimilar Market Size and Forecast by Type (2020-2025)
10.2.1 Global Infliximab and biosimilar Sales and Forecast by Type (2020-2025)
10.2.2 Global Infliximab and biosimilar Revenue and Forecast by Type (2020-2025)
10.2.3 Global Infliximab and biosimilar Price and Forecast by Type (2020-2025)
10.3 Japan Infliximab and biosimilar Market Size and Forecast by Type (2015-2025)
10.3.1 Japan Infliximab and biosimilar Market Size by Type (2015-2020)
10.3.2 Japan Infliximab and biosimilar Market Size and Forecast by Type (2020-2025)
11 Market Segment by Application
11.1 Global Infliximab and biosimilar Market Size by Application (2015-2020)
11.1.1 Global Infliximab and biosimilar Sales by Application (2015-2020)
11.1.2 Global Infliximab and biosimilar Revenue by Application (2015-2020)
11.1.3 Global Infliximab and biosimilar Price by Application (2015-2020)
11.2 Global Infliximab and biosimilar Market Size and Forecast by Application (2020-2025)
11.2.1 Global Infliximab and biosimilar Sales and Forecast by Application (2020-2025)
11.2.2 Global Infliximab and biosimilar Revenue and Forecast by Application (2020-2025)
11.2.3 Global Infliximab and biosimilar Price and Forecast by Application (2020-2025)
11.3 Japan Infliximab and biosimilar Market Size and Forecast by Application (2015-2025)
11.3.1 Japan Infliximab and biosimilar Market Size by Application (2015-2020)
11.3.2 Japan Infliximab and biosimilar Market Size and Forecast by Application (2020-2025)
12 Sales Channel, Distributors, Costumers, and Market Dynamics
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Distributors, Traders and Dealers
12.4.1 Market Opportunities
12.4.2 Market Risk
12.4.3 Market Driving Force
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Tables and Figures
List of Tables
Table 1. Global Infliximab and biosimilar Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Infliximab and biosimilar by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Infliximab and biosimilar Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Infliximab and biosimilar Market Size Overview by Geography (2015-2020) (USD Million)
Table 5. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 6. Janssen Biotech Infliximab and biosimilar Major Business
Table 7. Janssen Biotech Infliximab and biosimilar Total Revenue (USD Million) (2018-2019)
Table 8. Janssen Biotech SWOT Analysis
Table 9. Janssen Biotech Infliximab and biosimilar Product and Services
Table 10. Janssen Biotech Infliximab and biosimilar Sales (K MT), Price (USD/MT), Revenue, Gross Margin and Market Share (2018-2019)
Table 11. Merck and Co. Basic Information, Manufacturing Base and Competitors
Table 12. Merck and Co. Infliximab and biosimilar Major Business
Table 13. Merck and Co. Infliximab and biosimilar Total Revenue (USD Million) (2018-2019)
Table 14. Merck and Co. SWOT Analysis
Table 15. Merck and Co. Infliximab and biosimilar Product and Services
Table 16. Merck and Co. Infliximab and biosimilar Sales (K MT), Price (USD/MT), Revenue, Gross Margin and Market Share (2018-2019)
Table 17. Pfizer Basic Information, Manufacturing Base and Competitors
Table 18. Pfizer Infliximab and biosimilar Major Business
Table 19. Pfizer Infliximab and biosimilar Total Revenue (USD Million) (2018-2019)
Table 20. Pfizer SWOT Analysis
Table 21. Pfizer Infliximab and biosimilar Product and Services
Table 22. Pfizer Infliximab and biosimilar Sales (K MT), Price (USD/MT), Revenue, Gross Margin and Market Share (2018-2019)
Table 23. Global Infliximab and biosimilar Sales by Manufacturer (2018-2019) (K MT)
Table 24. Global Infliximab and biosimilar Revenue by Manufacturer (2018-2019) (USD Million)
Table 25. Key Players Infliximab and biosimilar Sales in Japan (2018-2019) (K MT)
Table 26. Key Players Infliximab and biosimilar Sales Market Share in Japan (2018-2019)
Table 27. Key Players Revenue of Infliximab and biosimilar in Japan (2018-2019) (USD Million)
Table 28. Global Infliximab and biosimilar Sales by Regions (2015-2020) (K MT)
Table 29. Global Infliximab and biosimilar Sales Market Share by Regions (2015-2020)
Table 30. Global Infliximab and biosimilar Revenue by Regions (2015-2020) (USD Million)
Table 31. Global Infliximab and biosimilar Sales and Forecast by Regions (2020-2025) (K MT)
Table 32. Global Infliximab and biosimilar Sales Market Share by Regions (2020-2025)
Table 33. Global Infliximab and biosimilar Revenue and Forecast by Regions (2020-2025) (USD Million)
Table 34. Global Infliximab and biosimilar Revenue Market Share by Regions (2020-2025) (USD Million)
Table 35. North America Infliximab and biosimilar Sales by Countries (2015-2020) (K MT)
Table 36. North America Infliximab and biosimilar Sales Market Share by Countries (2015-2020)
Table 37. North America Infliximab and biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 38. North America Infliximab and biosimilar Revenue Market Share by Countries (2015-2020)
Table 39. North America Infliximab and biosimilar Sales by Country (2020-2025) (K MT)
Table 40. North America Infliximab and biosimilar Sales Market Share by Country (2020-2025)
Table 41. North America Infliximab and biosimilar Revenue by Country (2020-2025) (USD Million)
Table 42. North America Infliximab and biosimilar Revenue Market Share by Country (2020-2025)
Table 43. Europe Infliximab and biosimilar Sales by Countries (2015-2020) (K MT)
Table 44. Europe Infliximab and biosimilar Sales Market Share by Countries (2015-2020)
Table 45. Europe Infliximab and biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 46. Europe Infliximab and biosimilar Revenue Market Share by Countries (2015-2020)
Table 47. Europe Infliximab and biosimilar Sales by Country (2020-2025) (K MT)
Table 48. Europe Infliximab and biosimilar Sales Market Share by Country (2020-2025)
Table 49. Europe Infliximab and biosimilar Revenue by Country (2020-2025) (USD Million)
Table 50. Europe Infliximab and biosimilar Revenue Market Share by Country (2020-2025)
Table 51. Asia-Pacific Infliximab and biosimilar Sales by Countries (2015-2020) (K MT)
Table 52. Asia-Pacific Infliximab and biosimilar Sales Market Share by Countries (2015-2020)
Table 53. Asia-Pacific Infliximab and biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 54. Asia-Pacific Infliximab and biosimilar Revenue Market Share by Countries (2015-2020)
Table 55. Asia-Pacific Infliximab and biosimilar Sales by Country (2020-2025) (K MT)
Table 56. Asia-Pacific Infliximab and biosimilar Sales Market Share by Country (2020-2025)
Table 57. Asia-Pacific Infliximab and biosimilar Revenue by Country (2020-2025) (USD Million)
Table 58. Asia-Pacific Infliximab and biosimilar Revenue Market Share by Country (2020-2025)
Table 59. South America Infliximab and biosimilar Sales by Countries (2015-2020) (K MT)
Table 60. South America Infliximab and biosimilar Sales Market Share by Countries (2015-2020)
Table 61. South America Infliximab and biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 62. South America Infliximab and biosimilar Revenue Market Share by Countries (2015-2020)
Table 63. South America Infliximab and biosimilar Sales by Country (2020-2025) (K MT)
Table 64. South America Infliximab and biosimilar Sales Market Share by Country (2020-2025)
Table 65. South America Infliximab and biosimilar Revenue by Country (2020-2025) (USD Million)
Table 66. South America Infliximab and biosimilar Revenue Market Share by Country (2020-2025)
Table 67. Middle East & Africa Infliximab and biosimilar Sales by Countries (2015-2020) (K MT)
Table 68. Middle East & Africa Infliximab and biosimilar Sales Market Share by Countries (2015-2020)
Table 69. Middle East & Africa Infliximab and biosimilar Revenue by Countries (2015-2020) (USD Million)
Table 70. Middle East & Africa Infliximab and biosimilar Revenue Market Share by Countries (2015-2020)
Table 71. Middle East & Africa Infliximab and biosimilar Sales by Country (2020-2025) (K MT)
Table 72. Middle East & Africa Infliximab and biosimilar Sales Market Share by Country (2020-2025)
Table 73. Middle East & Africa Infliximab and biosimilar Revenue by Country (2020-2025) (USD Million)
Table 74. Middle East & Africa Infliximab and biosimilar Revenue Market Share by Country (2020-2025)
Table 75. Japan Infliximab and biosimilar Sales by Type (2015-2020) (K MT)
Table 76. Japan Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 77. Japan Infliximab and biosimilar Revenue by Type (2015-2020) (USD Million)
Table 78. Japan Infliximab and biosimilar Revenue Market Share by Type (2015-2020)
Table 79. Japan Infliximab and biosimilar Sales by Type (2020-2025) (K MT)
Table 80. Japan Infliximab and biosimilar Sales Market Share by Type (2020-2025)
Table 81. Japan Infliximab and biosimilar Revenue by Type (2020-2025) (USD Million)
Table 82. Japan Infliximab and biosimilar Revenue Market Share by Type (2020-2025)
Table 83. Global Infliximab and biosimilar Sales by Application (2015-2020) (K MT)
Table 84. Global Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 85. Global Infliximab and biosimilar Revenue by Application (2015-2020) (USD Million)
Table 86. Global Infliximab and biosimilar Revenue Market Share by Application (2015-2020)
Table 87. Global Infliximab and biosimilar Price by Application (2015-2020) (USD/MT)
Table 88. Global Infliximab and biosimilar Sales by Application (2020-2025) (K MT)
Table 89. Global Infliximab and biosimilar Sales Market Share by Application (2020-2025)
Table 90. Global Infliximab and biosimilar Revenue by Application (2020-2025) (USD Million)
Table 91. Global Infliximab and biosimilar Revenue Market Share by Application (2020-2025)
Table 92. Global Infliximab and biosimilar Price by Application (2020-2025) (USD/MT)
Table 93. Japan Infliximab and biosimilar Sales by Application (2015-2020) (K MT)
Table 94. Japan Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 95. Japan Infliximab and biosimilar Revenue by Application (2015-2020) (USD Million)
Table 96. Japan Infliximab and biosimilar Revenue Market Share by Application (2015-2020)
Table 97. Japan Infliximab and biosimilar Sales by Application (2020-2025) (K MT)
Table 98. Japan Infliximab and biosimilar Sales Market Share by Application (2020-2025)
Table 99. Japan Infliximab and biosimilar Revenue by Application (2020-2025) (USD Million)
Table 100. Japan Infliximab and biosimilar Revenue Market Share by Application (2020-2025)
Table 101. Direct Channel Pros & Cons
Table 102. Indirect Channel Pros & Cons
Table 103. Distributors/Traders/ Dealers List
Table 104. Customers of Infliximab and biosimilar
Table 105. Market Opportunities in Next Few Years
Table 106. Market Risks Analysis
Table 107. Market Drivers
List of Figures
Figure 1. Infliximab and biosimilar Picture
Figure 2. Global Infliximab and biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 3. Infliximab Picture
Figure 4. infliximab-dyyb Picture
Figure 5. infliximab-abda Picture
Figure 6. Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 7. Crohn's Disease Picture
Figure 8. Pediatric Crohn's Disease Picture
Figure 9. Ulcerative Colitis Picture
Figure 10. Rheumatoid Arthritis Picture
Figure 11. Ankylosing Spondylitis Picture
Figure 12. Psoriatic Arthritis Picture
Figure 13. Plaque Psoriasis Picture
Figure 14. Global Infliximab and biosimilar Market Status and Outlook (2015-2025) (USD Million)
Figure 15. Global Infliximab and biosimilar Sales Growth Rate (2015-2025) (K MT)
Figure 16. Global Infliximab and biosimilar Sales Market Share by Manufacturer in 2019
Figure 17. Global Infliximab and biosimilar Revenue Market Share by Manufacturer in 2019
Figure 18. Key Players Infliximab and biosimilar Revenue Market Share in Japan in 2019
Figure 19. Global Top 5 Infliximab and biosimilar Manufacturer Market Share in 2019
Figure 20. Top 3 Infliximab and biosimilar Players Market Share in Japan in 2019
Figure 21. Global Infliximab and biosimilar Revenue Market Share by Regions in 2019
Figure 22. North America Infliximab and biosimilar Sales YoY Growth (2015-2025) (K MT)
Figure 23. North America Infliximab and biosimilar Revenue YoY Growth (2015-2025) (USD Million)
Figure 24. Europe Infliximab and biosimilar Sales YoY Growth (2015-2020) (K MT)
Figure 25. Europe Infliximab and biosimilar Revenue YoY Growth (2015-2020) (USD Million)
Figure 26. Asia-Pacific Infliximab and biosimilar Sales YoY Growth (2015-2020) (K MT)
Figure 27. Asia-Pacific Infliximab and biosimilar Revenue YoY Growth (2015-2020) (USD Million)
Figure 28. South America Infliximab and biosimilar Sales YoY Growth (2015-2020) (K MT)
Figure 29. South America Infliximab and biosimilar Revenue YoY Growth (2015-2020) (USD Million)
Figure 30. Middle East & Africa Infliximab and biosimilar Sales YoY Growth (2015-2020) (K MT)
Figure 31. Middle East & Africa Infliximab and biosimilar Revenue YoY Growth (2015-2020) (USD Million)
Figure 32. North America Infliximab and biosimilar Sales Market Share by Country in 2019
Figure 33. North America Infliximab and biosimilar Revenue Market Share by Country in 2019
Figure 34. United States Infliximab and biosimilar Market Size and Growth Rate (2015-2025) (USD Million)
Figure 35. Canada Infliximab and biosimilar Market Size and Growth Rate (2015-2025) (USD Million)
Figure 36. Mexico Infliximab and biosimilar Market Size and Growth Rate (2015-2020) (USD Million)
Figure 37. Europe Infliximab and biosimilar Revenue Market Share by Country in 2019
Figure 38. Germany Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 39. United Kingdom Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 40. France Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 41. Russia Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 42. Italy Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 43. Asia-Pacific Infliximab and biosimilar Sales Market Share by Region 2018
Figure 44. Asia-Pacific Infliximab and biosimilar Revenue Market Share by Region 2018
Figure 45. China Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 46. Japan Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 47. Korea Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 48. India Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 49. Southeast Asia Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 50. Australia Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 51. South America Infliximab and biosimilar Sales Market Share by Country in 2019
Figure 52. South America Infliximab and biosimilar Revenue Market Share by Country in 2019
Figure 53. Brazil Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 54. Argentina Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 55. Saudi Arabia Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 56. Turkey Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 57. Egypt Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 58. South Africa Infliximab and biosimilar Market Size Growth Rate (2015-2025) (USD Million)
Figure 59. Global Revenue Market Share of Infliximab and biosimilar by Type in 2019
Figure 60. Global Revenue Market Share of Infliximab and biosimilar by Application in 2019
Figure 61. Sales Channel: Direct Channel vs Indirect Channel
Companies Mentioned
Janssen Biotech
Merck and Co.
Pfizer
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets